Delving into the Latest Updates on Nicoboxil/Nonivamide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Nicoboxil, beta-Butoxyethyl nicotinate, Finalgon

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

ArthritisBursitisLow Back Pain+ [3]

Inactive Indication-

Originator Organization

Sanofi

Active Organization

Sanofi

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Germany (11 Jul 2012),

ArthritisBursitisLow Back Pain+ [3]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC29H44N2O6

InChIKeyGBZLDDMGSWUIKV-UHFFFAOYSA-N

CAS Registry93746-32-8

A Multi-centre, Double-blind, Randomised, Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of Topically Applied Hyperemisation-inducing Ointment (2cm Ointment Line Per Application; up to 3 Times Daily for up to 4 Days) Containing 2.5% Nicoboxil/0.4% Nonivamide Versus 2.5% Nicoboxil, 0.4% Nonivamide and Placebo in Patients 18 to 65 Years of Age With Acute Low Back Pain

The aim of this study is to assess the efficacy and tolerability of Nicoboxil/Nonivamide ointment in comparison to Nicoboxil, Nonivamide, and placebo ointments for the treatment of acute low back pain.

Start Date01 Oct 2012

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Nicoboxil/Nonivamide

Login to view more data

100 Translational Medicine associated with Nicoboxil/Nonivamide

Login to view more data

100 Patents (Medical) associated with Nicoboxil/Nonivamide

Login to view more data

24

Literatures (Medical) associated with Nicoboxil/Nonivamide

01 Nov 2021·International Journal of Sports MedicineQ4 · MEDICINE

No Influence of Nonivamide-nicoboxil on the Peak Power Output in Competitive Sportsmen

Q4 · MEDICINE

Article

Author: Schörkmaier, Theresa ; Bloch, Wilhelm ; Wahl, Yvonne ; Brinkmann, Christian ; Wahl, Patrick

AbstractRecent studies have shown that the oxygenated hemoglobin level can be enhanced during rest through the application of nonivamide-nicoboxil cream. However, the effect of nonivamide-nicoboxil cream on oxygenation and endurance performance under hypoxic conditions is unknown. Therefore, the purpose of this study was to investigate the effects of nonivamide-nicoboxil cream on local muscle oxygenation and endurance performance under normoxic and hypoxic conditions. In a cross-over design, 13 athletes (experienced cyclists or triathletes [age: 25.2±3.5 years; VO2max 62.1±7.3 mL·min−1·kg−1]) performed four incremental exercise tests on the cycle ergometer under normoxic or hypoxic conditions, either with nonivamide-nicoboxil or placebo cream. Muscle oxygenation was recorded with near-infrared spectroscopy. Capillary blood samples were taken after each step, and spirometric data were recorded continuously. The application of nonivamide-nicoboxil cream increased muscle oxygenation at rest and during different submaximal workloads as well as during physical exhaustion, irrespective of normoxic or hypoxic conditions. Overall, there were no significant effects of nonivamide-nicoboxil on peak power output, maximal oxygen uptake or lactate concentrations. Muscle oxygenation is significantly higher with the application of nonivamide-nicoboxil cream. However, its application does not increase endurance performance.

01 May 2016·European Journal of Applied Physiology

Topical application of cream containing nonivamide and nicoboxil does not enhance the performance of experienced cyclists during a 4-km time-trial

Article

Author: Holmberg, Hans-Christer ; Zinner, Christoph ; Sperlich, Billy

PURPOSETopical application of nonivamide-nicoboxil cream to resting legs has been shown to enhance the level of oxygenated haemoglobin in leg muscles 15 min later. Here, we examined whether such application improves the performance of experienced cyclists in a subsequent 4-km time-trial.METHODSNine male cyclists [26 ± 8 years; 176 ± 9 cm; 73.5 ± 12.8 kg; peak oxygen uptake: 50.7 ± 4.0 mL min(-1) kg(-1) (mean ± SD)] performed three 4-km time-trials on an ergometer with either topical application of nonivamide-nicoboxil cream (CREAM) or cream without active components (SHAM) to both their thigh muscles or no application (CONTROL).RESULTSOnly the skin temperature immediately before and after the time-trial was higher with cream than SHAM and CONTROL (best p < 0.001, best d = 1.16). All other parameters evaluated, i.e., the average power output during the time-trial (p > 0.05, best d = 0.08), the tissue saturation index of the m. vastus lateralis (p > 0.05, best d = 0.57), cardiac output, heart rate, oxygen uptake, blood lactate concentration, and perceived exertion (p > 0.05, best d = 1.1) were similar under all three conditions.CONCLUSIONSOur present findings reveal that topical application of cream containing nonivamide and nicoboxil to the thighs of cyclists prior to a 4-km time-trial does not improve their power output, saturation of the m. vastus lateralis with oxygen, oxygen uptake, heart rate, cardiac parameters, or perceived level of exertion.

01 Feb 2016·European Journal of PainQ2 · MEDICINE

Efficacy and safety of nicoboxil/nonivamide ointment for the treatment of acute pain in the low back – A randomized, controlled trial

Q2 · MEDICINE

Article

Author: Weiser, T. ; Pisternick‐Ruf, W. ; Schiffer, T. ; Gaubitz, M. ; Holm, C. ; Richter, E.

AbstractBackgroundUntil now, nonivamide/nicoboxil ointment has not been tested in a randomized trial for the treatment of acute non‐specific low back pain.MethodsThis phase III randomized, double‐blind, active‐ and placebo‐controlled, multi‐centre trial investigated efficacy, safety and tolerability of topical nicoboxil 2.5%/nonivamide 0.4% for treatment of acute non‐specific low back pain [primary endpoint: pain intensity (PI) difference between pre‐dose baseline and 8 h after the first application].ResultsPatients (n = 805), 18–74 years of age were treated for up to 4 days with nicoboxil 2.5%/nonivamide 0.4%, nicoboxil 2.5%, nonivamide 0.4% or placebo ointment. Pre‐dose baseline pain intensity (6.6 on a 0‐ to 10‐point numerical rating scale) was reduced by 1.049 points with placebo, by 1.428 points with nicoboxil, by 2.252 points with nonivamide and by 2.410 points with nicoboxil/nonivamide after 8 h (p < 0.0001 for nicoboxil/nonivamide vs. placebo, nicoboxil; p = 0.4171 for nicoboxil/nonivamide vs. nonivamide). At the end of treatment, the combination provided more pronounced PI reduction (3.540 points) compared with nicoboxil (2.371, p < 0.0001), nonivamide (3.074, p = 0.0259) and placebo (1.884, p < 0.0001). Low back mobility scores on Day 1 were better for the combination compared with all other treatments (p < 0.044); on Day 2–4, scores were better than for placebo and nicoboxil (p < 0.003). Patients assessed efficacy of the combination as greater than of the comparators (p ≤ 0.0129). All treatments were tolerated well. No treatment‐related serious adverse events were reported.ConclusionNicoboxil/nonivamide ointment is an effective, well‐tolerated medication for the treatment of acute non‐specific low back pain.

100 Deals associated with Nicoboxil/Nonivamide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	M02AB	DB12911

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Arthritis	Germany	Sanofi	11 Jul 2012
Bursitis	Germany	Sanofi	11 Jul 2012
Low Back Pain	Germany	Sanofi	11 Jul 2012
Sciatica	Germany	Sanofi	11 Jul 2012
Tenosynovitis	Germany	Sanofi	11 Jul 2012
Vascular Diseases	Germany	Sanofi	11 Jul 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02300311 (TOPICAL NONIVAMIDE/NICOBOXIL, CTgov)	Phase 3	Acute low back pain	138	placebo matching nonivamide + nicoboxil (Finalgon cream)	kpjjzxohff(onhthsbebc) = vhprfqqrcv kxlxlimsjq (sqrtuswsjn, cxczpbhjjm - ohupzcandn) View more	-	13 Sep 2016
NCT01708915 (CTgov)	Phase 3	Acute low back pain	805	placebo matching nonivamide + nicoboxil (Placebo)	xqgrrgzdqo(htlovfiimc) = evrbtrcldv fttmgipjbn (jajedwgxtc, chkawqgewv - mvgxfsrzcw) View more	-	15 May 2014
NCT01708915 (CTgov)	Phase 3	Acute low back pain	805	nicoboxil (Nicoboxil)	xqgrrgzdqo(htlovfiimc) = qxfkgbpiki fttmgipjbn (jajedwgxtc, nswuhhxkag - dixhajfgxl) View more	-	15 May 2014